Evaluation of an Automated System (Optimate) for Substrate-Labeled Fluorescent Immunoassays
- 1 March 1985
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 7 (1) , 108-114
- https://doi.org/10.1097/00007691-198503000-00019
Abstract
Performance characteristics of substrate-labeled fluorescent immunoassays for the drugs phenytoin, phenobarbital, primidone, carbamazepine, theophylline, gentamicin, tobramycin, amikacin and quinidine run on an Optimate automated fluorometric analyzer, were compared with those of automated enzyme multiplied immunoassays (EMIT) for the same drugs performed on a Cobas centrifugal analyzer for patient samples and controls. For 100 patient samples assayed by both systems for each drug, excellent correlations were obtained, with correlation coefficients ranging from 0.96 - 0.99. Very good within-run (n = 10) and between-run (n = 30) precision was obtained by both methods. Values for controls and clinical specimens by the Optimate methods, calculated using the same-day calibration curves, were not significantly different from those calculated from calibration curves stored 14 days, indicating at least 14 day curve stability for all assays.This publication has 5 references indexed in Scilit:
- Automation of the Homogeneous Substrate-Labeled Fluorescent Immunoassay for Theophylline in SerumTherapeutic Drug Monitoring, 1982
- Evaluation of four assay methods for determination of tobramycin in human serum.Clinical Chemistry, 1982
- Substrate-labeled fluorescent immunoassay for amikacin in human serumAntimicrobial Agents and Chemotherapy, 1980
- Substrate-Labeled Fluorescent Immunoassay for PhenobarbitalTherapeutic Drug Monitoring, 1980
- Substrate-labeled fluorescent immunoassay for phenytoin in human serum.Clinical Chemistry, 1979